Search results for "Growth factor"

showing 10 items of 1300 documents

A novel caryophyllene type sesquiterpene lactone from Asparagus falcatus (Linn.); Structure elucidation and anti-angiogenic activity on HUVECs

2011

Abstract In this study the novel caryophyllene type sesquiterpene lactone (aspfalcolide) has been isolated from the leaves of Asparagus falcatus (Linn.) and characterized by IR, 1D NMR, 2D NMR, EI–MS, HR–ESI–MS and X-ray single crystal diffraction analysis. The aspfalcolide crystallizes in the orthorhombic space group P212121 with a = 6.37360(10), b = 7.6890(2), c = 27.3281(6) A, α = β = γ = 90° and Z = 4. One intermolecular O–H⋯O hydrogen bond enforces these natural molecules to form infinite chains through the crystal. Aspfalcolide was screened for its anti-angiogenic activity in human umbilical vein endothelial cells (HUVECs) and the result showed the remarkable inhibitory effect of aspf…

Models MolecularVascular Endothelial Growth Factor AStereochemistryMolecular ConformationAngiogenesis InhibitorsSesquiterpene lactoneUmbilical veinLactoneschemistry.chemical_compoundCell MovementDrug DiscoveryHuman Umbilical Vein Endothelial CellsHumansta116Cell ProliferationAsparagus falcatusPolycyclic SesquiterpenesPharmacologychemistry.chemical_classificationTube formationbiologyHydrogen bondCaryophylleneOrganic ChemistryGeneral Medicinebiology.organism_classificationchemistryOrthorhombic crystal systemAsparagus PlantSesquiterpenesTwo-dimensional nuclear magnetic resonance spectroscopyEuropean Journal of Medicinal Chemistry
researchProduct

Application of propolis extract, nanovitamin C and nanovitamin E to prevent alveolar osteitis after impacted lower third molar surgery. A randomized,…

2020

Background Propolis has anti-inflammatory, analgesic and healing properties. The purpose of this study was to determine whether a gel containing 2% of propolis extract, 0.2% of ascorbic acid and 0.2% of tocopherol acetate is effective in preventing surgical complications related to impacted lower third molar extractions. Material and Methods A randomized, double-blind, split-mouth study was performed. Fifteen patients were recruited who needed bilateral impacted lower third molar extractions with a similar surgical difficulty. A test or placebo gel was administered randomly inside post-extraction sockets. Each patient was instructed to apply the gel 3 times/day in the surgical wound for a w…

MolarAdultAdolescentVisual analogue scalesalivary glandsAnalgesicDentistryDry SocketPilot ProjectsMandiblePlaceboTrismusPropolis03 medical and health sciencesYoung Adult0302 clinical medicinehead and neck neoplasmsDouble-Blind MethodmedicineEdemaHumansvascular endothelial growth factorsGeneral DentistryUNESCO:CIENCIAS MÉDICASPain Postoperativebusiness.industryPlant ExtractsResearchTooth ImpactedSurgical wound030206 dentistryAscorbic acidmedicine.diseasesalivary gland neoplasmsOtorhinolaryngologyTooth ExtractionSurgeryMolar ThirdprognosisOsteitismedicine.symptomOral Surgerybusiness
researchProduct

In murine 3T3 fibroblasts, different second messenger pathways resulting in the induction of NO synthase II (iNOS) converge in the activation of tran…

1996

Transcription factor NF-kappaB is essential for the induction of nitric oxide synthase (NOS) II (iNOS) by bacterial lipopolysaccharide in murine macrophages (Xie, Q. W., Kashiwabara, Y., and Nathan, C. (1994) J. Biol. Chem. 269, 4705-4708). In 3T3 fibroblasts, agents other than cytokines are efficacious inducers of NOS II expression. In addition to cytokines such as interferon-gamma or tumor necrosis factor-alpha, protein kinase C-stimulating agents such as tetradecanoylphorbol-13-acetate, or cyclic AMP-elevating agents such as forskolin and 8-bromo-cAMP markedly increased NOS II mRNA (measured by Sl nuclease and RNase protection analyses), NOS II protein (determined by Western blotting), a…

Molecular Sequence DataBiochemistrySecond Messenger SystemsDexamethasoneGene Expression Regulation Enzymologicchemistry.chemical_compoundMicePyrrolidine dithiocarbamateTransforming Growth Factor betaAnimalsHumansAmino Acid SequenceRNA MessengerNuclear proteinProtein kinase AMolecular BiologyTranscription factorProtein Kinase CDNA PrimersForskolinbiologyBase SequenceNF-kappa BReceptor Protein-Tyrosine KinasesCell Biology3T3 CellsMolecular biologyCyclic AMP-Dependent Protein KinasesActinsNitric oxide synthasechemistryEnzyme InductionSecond messenger systembiology.proteinTumor necrosis factor alphaNitric Oxide SynthaseThe Journal of biological chemistry
researchProduct

Ramucirumab and its use in gastric cancer treatment

2014

Abstract: The inhibition of the mechanisms of tumor neo-angiogenesis represents a milestone that in the last 10 years has seen the advent of numerous molecules to target action against the vascular endothelial growth factor (VEGF). More recently, new molecules have been developed that inhibit tumor spread by the blockade of specific VEGF receptors (VEGFRs), thereby preventing the binding of a ligand to its receptor and the cascade of proliferative events downstream. Ramucirumab is a fully humanized IgG1 monoclonal antibody that performs its action by blocking the isoform 2 of the VEGF receptor (VEGFR-2). Numerous preclinical and clinical studies have demonstrated its activity in several sol…

Monoclonal antibodyGene isoformmedicine.drug_classAngiogenesisAngiogenesis; Gastroesophageal junction cancer; Metastatic gastric cancer; Monoclonal antibody; Ramucirumab; VEGF receptors; Pharmacology; Pharmacology (medical)Antineoplastic AgentsPharmacologyAntibodies Monoclonal HumanizedGastroesophageal junction cancerMonoclonal antibodyRamucirumabRamucirumabchemistry.chemical_compoundStomach NeoplasmsmedicineHumansPharmacology (medical)ReceptorVEGF receptorsPharmacologyClinical Trials as Topicbusiness.industryPharmacology. TherapyVEGF receptorAntibodies MonoclonalLigand (biochemistry)Vascular Endothelial Growth Factor Receptor-2BlockadeVascular endothelial growth factorAngiogenesichemistryAngiogenesisbusinessMetastatic gastric cancerDrugs of Today
researchProduct

Impact of carbon ion irradiation on epidermal growth factor receptor signaling and glioma cell migration in comparison to conventional photon irradia…

2013

PURPOSE: Radiotherapy of malignant gliomas may be limited by an interference of radiation with the migratory potential of tumor cells. Therefore, the influence of conventional photon and modern carbon ion ((12)C) irradiation on glioblastoma cell migration and on epidermal growth factor receptor-related (EGFR) signaling was investigated in vitro. MATERIALS AND METHods: EGFR overexpressing glioblastoma cell lines U87 EGFR++ and LN229 EGFR++ were irradiated with 0, 2 or 6 Gy photons or (12)C heavy ions. Migration was analyzed 24 h after treatment in a standardized Boyden Chamber assay. At different time points EGFR, protein kinase B (PKB/AKT) and extracellular signal-related kinases (ERK1/2) w…

MotilityRadiation DosageCell MovementEpidermal growth factorCell Line TumorGliomamedicineHumansHeavy IonsRadiology Nuclear Medicine and imagingEpidermal growth factor receptorProtein kinase BPhotonsRadiological and Ultrasound TechnologybiologyChemistryKinaseDose-Response Relationship Radiationmedicine.diseaseCarbonErbB ReceptorsCell cultureImmunologyCancer researchbiology.proteinPhosphorylationGlioblastomaSignal TransductionInternational Journal of Radiation Biology
researchProduct

Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T Cells

2013

International audience; Bleomycin (BLM) is an anticancer drug currently used for the treatment of testis cancer and Hodgkin lymphoma. This drug triggers cancer cell death via its capacity to generate radical oxygen species (ROS). However, the putative contribution of anticancer immune responses to the efficacy of BLM has not been evaluated. We make here the observation that BLM induces immunogenic cell death. In particular, BLM is able to induce ROS-mediated reticulum stress and autophagy, which result in the surface exposure of chaperones, including calreticulin and ERp57, and liberation of HMBG1 and ATP. BLM induces anti-tumor immunity which relies on calreticulin, CD8(+) T cells and inte…

MouseCancer TreatmentCD8-Positive T-LymphocytesT-Lymphocytes RegulatoryHematologic Cancers and Related DisordersMice0302 clinical medicineTransforming Growth Factor beta[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyCytotoxic T cellImmune Response0303 health sciencesMultidisciplinaryCell DeathbiologyQRFOXP3Animal ModelsHematology3. Good healthCell biologyOncology030220 oncology & carcinogenesisMedicine[SDV.IMM]Life Sciences [q-bio]/ImmunologyImmunogenic cell deathFemaleLymphomasOncology AgentsResearch ArticleTumor Immunologycongenital hereditary and neonatal diseases and abnormalitiesProgrammed cell death[SDV.IMM] Life Sciences [q-bio]/ImmunologyScienceImmunologyAntineoplastic Agentschemical and pharmacologic phenomenaBleomycin03 medical and health sciencesModel OrganismsImmune systemCell Line TumorAnimalsHumansBiologyCell Proliferation030304 developmental biologyHodgkin Lymphomaurogenital systemCell growthImmunitynutritional and metabolic diseasesImmunologic SubspecialtiesChemotherapy and Drug TreatmentImmunity InnateCancer cellbiology.proteinClinical ImmunologyCalreticulinPLoS ONE
researchProduct

Regulatory T Cells and IL-10 Independently Counterregulate Cytotoxic T Lymphocyte Responses Induced by Transcutaneous Immunization

2011

Background: The imidazoquinoline derivate imiquimod induces inflammatory responses and protection against transplanted tumors when applied to the skin in combination with a cognate peptide epitope (transcutaneous immunization, TCI). Here we investigated the role of regulatory T cells (Treg) and the suppressive cytokine IL-10 in restricting TCI-induced cytotoxic T lymphocyte (CTL) responses. Methodology/Principal Findings: TCI was performed with an ointment containing the TLR7 agonist imiquimod and a CTL epitope was applied to the depilated back skin of C57BL/6 mice. Using specific antibodies and FoxP3-diphteria toxin receptor transgenic (DEREG) mice, we interrogated inhibiting factors after…

Mouselcsh:MedicineEpitopes T-LymphocyteAdaptive ImmunityT-Lymphocytes RegulatoryImmune toleranceMiceMedicineCytotoxic T celllcsh:ScienceImmune ResponseSkinMice KnockoutB-LymphocytesMultidisciplinaryImiquimodFOXP3hemic and immune systemsForkhead Transcription FactorsAnimal ModelsFlow CytometryInterleukin-10Interleukin 10medicine.anatomical_structureAminoquinolinesCytokinesIntercellular Signaling Peptides and ProteinsImmunotherapyResearch ArticleHeparin-binding EGF-like Growth FactorT cellImmune CellsImmunologychemical and pharmacologic phenomenaImmune SuppressionImmunomodulationImmune systemModel OrganismsImmune ToleranceAnimalsBiologyB cellbusiness.industrylcsh:RImmunityMice Inbred C57BLCTL*Immune SystemImmunologyImmunologic Techniqueslcsh:QImmunizationbusinessT-Lymphocytes CytotoxicPLoS ONE
researchProduct

Single nucleotide polymorphisms of the vascular endothelial growth factor gene associated with incidence of oral squamous cell carcinoma

2010

J Oral Pathol Med (2010) 39: 786–792 Background:  Vascular endothelial growth factor (VEGF) plays an important role in promoting angiogenesis and is overexpressed in several malignancies. Polymorphisms of the VEGF gene can alter VEGF protein expression, which may be biologically significant and account for heterogeneity in disease risk and outcome. The aim of this case–control study was to evaluate potential associations between single nucleotide polymorphisms (SNP) of the VEGF gene with susceptibility of oral squamous cell carcinoma (OSCC). Patients and methods:  Five VEGF SNP (−1154 G/A, +405 G/C, +936 C/T, −2578 C/A and −460 C/T) were determined in peripheral blood isolated from 80 patie…

Mouth neoplasmCancer ResearchPathologymedicine.medical_specialtyAngiogenesisSingle-nucleotide polymorphismBiologyPathology and Forensic MedicineVascular endothelial growth factorstomatognathic diseaseschemistry.chemical_compoundVascular endothelial growth factor AOtorhinolaryngologychemistrymedicineCancer researchPeriodonticsBiomarker (medicine)SNPOral SurgeryAlleleJournal of Oral Pathology & Medicine
researchProduct

PROX1 transcription factor controls rhabdomyosarcoma growth, stemness, myogenic properties and therapeutic targets

2022

Funding Information: ACKNOWLEDGMENTS. We would like to thank Dr. Tuomas Tammela and Dr. Monika Ehnmann for providing RMS cell lines and Dr. Jenny Högström for discussions and comments during the project. Kirsi Mattinen, Jefim Brodkin, Maxime Laird, Manon Gruchet, Ilse Paetau, Tanja Laakkonen, and Tapio Tainola are acknowledged for their excellent technical help. We also thank the Laboratory Animal Center at the University of Helsinki for expert animal care, the Biomedicum Imaging Unit for microscope support, the Biomedicum Functional Genomics Unit for the RNAseq experiments and the FIMM Technology Centre High Throughput Biomedicine for the drug sensitivity and resistance testing. Our first …

MultidisciplinarysarcomaFGFRPROX13122 CancersGenes HomeoboxReceptors Fibroblast Growth FactorsarkoomaGene Expression RegulationRhabdomyosarcomaHumanscancersyöpätauditmyogenesis3111 BiomedicineChildTranscriptomeProtein Kinase InhibitorsTranscription Factors
researchProduct

An experimental study of muscular injury repair in a mouse model of notexin-induced lesion with EPI® technique

2015

BACKGROUND: The mechanisms of muscle injury repair after EPI® technique, a treatment based on electrical stimulation, have not been described. This study determines whether EPI® therapy could improve muscle damage. METHODS: Twenty-four rats were divided into a control group, Notexin group (7 and 14 days) and a Notexin + EPI group. To induce muscle injury, Notexin was injected in the quadriceps of the left extremity of rats. Pro-inflammatory interleukin 1-beta (IL-1beta) and tumoral necrosis factor-alpha (TNF-alpha) were determined by ELISA. The expression of receptor peroxisome gamma proliferator activator (PPAR-gamma), vascular endothelial growth factor (VEGF) and vascular endothelial grow…

Muscle tissuePathologymedicine.medical_specialtyNecrosisPhysical Therapy Sports Therapy and RehabilitationStimulationInjuryLesionchemistry.chemical_compoundInternal medicineMedicineOrthopedics and Sports MedicineReceptorbusiness.industryActivator (genetics)RehabilitationMúsculs -- MalaltiesInterleukinVascular endothelial growth factorEPImedicine.anatomical_structureEndocrinologychemistryNotexin-inducedTechniqueMusclemedicine.symptombusinessResearch Article
researchProduct